Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Epub ahead of print 12 November 2013.
International Task Force for Prevention of Coronary Heart Disease, International Atherosclorosis Society. 2009 guide to prevention of coronary heart disease. Barcelona, Spain: Prous Science, SAU, 2009.
4.
ReinerZCatapanoALDe BackerG. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J2011; 32: 1769–1818.
5.
RayKKKasteleinJJBoekholdtSM. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J2014; 35: 960–968.
6.
JacobsonTAItoMKMakiKC. National Lipid Association recommendations for patient-centered management of dyslipidemia. Part 1 – executive summary. J Clin Lipidol2014; 8: 473–488.
7.
Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia – full report. J Clin Lipidol2014; 8: 29–60.
8.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3421.
9.
GrundySMCleemanJIMerzCN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004; 110: 227–239.
10.
American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care2014; 37(Suppl. 1): S14–S80.
11.
LaRosaJCGrundySMWatersDD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 352: 1425–1435.
12.
CannonCPBraunwaldEMcCabeCH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004; 350: 1495–1504.
13.
Cholesterol Treatment Trialists Collaboration, BaigentCBlackwellL. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet2010; 376: 1670–1681.
14.
CohenJCBoerwinkleEMosleyTHJr. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med2006; 354: 1264–1272.
15.
PuriRNissenSEShaoM. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J2013; 34: 3182–3190.
16.
MuntnerPColantonioLDCushmanM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA2014; 311: 1406–1415.
17.
RidkerPMCookNR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet2013; 382: 1762–1765.
18.
KavousiMLeeningMJNanchenD. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA2014; 311: 1416–1423.
19.
PencinaMJNavar-BogganAMD’AgostinoRBSr. Application of new cholesterol guidelines to a population-based sample. N Engl J Med2014; 370: 1422–1431.
20.
Amin NP, Martin SS, Blaha MJ, et al. Headed in the right direction but at risk for miscalculation: A critical appraisal of the 2013 ACC/AHA Risk Assessment Guidelines. J Am Coll Cardiol 2014; 63: 2789–2794.
21.
FinegoldJAManistyCHGoldacreB. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol2014; 21: 464–474.
22.
SattarNPreissDMurrayHM. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet2010; 375: 735–742.
23.
PreissDSeshasaiSRWelshP. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA2011; 305: 2556–2564.
24.
SattarNAGinsbergHRayK. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atheroscler Suppl2014; 15: 1–15.
25.
Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: Gluttony in the time of statins? JAMA Intern Med 2014; 174: 1038–1045.
26.
OngKLWatersDDMessigM. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol2014; 113: 1593–1598.
27.
ZetheliusBGudbjörnsdottirSEliassonB. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 daiabetes: Report from the Swedish National Diabetes Register. Eur J Prev Cardiol2014; 21: 244–252.
28.
GibbsBBBrancatiFLChenH. for the Look AHEAD Research Group). Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur J Prev Cardiol2014; 21: 608–617.
